Our Story
Starting with a
Bold Idea
Take a decades-old molecule and advance it with today’s clinical, manufacturing, regulatory, and scientific standards.
Revisiting psychedelics through a modern lens
The treatment potential of LSD sits at the intersection of urgent unmet medical need and promising science. Millions with major depressive disorder (MDD) and generalized anxiety disorder (GAD) do not respond well to current treatments, which often require daily dosing, can take weeks to work, and often fail to deliver meaningful relief.
Compounds like LSD offer a compelling potential alternative. Extensively researched in the mid-20th century, with over 1,000 published studies, it is among the best-characterized psychedelics and longest-researched psychoactive substances.
At Definium, we are revisiting psychedelics through a modern lens, incorporating advances in neuroscience and clinical research with scientific and regulatory rigor to generate high-quality, evidence-based data to better understand safety, efficacy, and mechanisms of action.
What We Do
Our strategy turns evidence into impact
Our history and evolution
Definium Therapeutics was founded
Our roots date back to 2019 when we were known as MindMed. Since then, we’ve delivered a clear, differentiated vision and have executed with discipline, establishing ourselves as a leader in psychiatric drug development.
New leadership guides our future
In 2021, we reached a major milestone with our public listing on NASDAQ, marking a new chapter of growth and visibility.
In the same period, Robert Barrow was appointed CEO, bringing new leadership to guide the company’s next phase.
Regulatory milestone advances our clinical pipeline
In 2022, the U.S. Food and Drug Administration (FDA) cleared our investigational new drug (IND) application, allowing our Phase 2b dose-optimization trial of DT120 for the treatment of GAD to proceed.
Results signal strong potential for clinical development
In 2023, we announced positive top-line results from our Phase 2b trial of DT120 in GAD, the first efficacy study of DT120 and the first study to assess the standalone drug effects of DT120 in the absence of any psychotherapeutic intervention.
Major milestones achieved, signaling strong momentum
A series of major milestones signaled strong momentum across our pipeline and corporate growth, including:
- The pipeline continued to expand with the completion of a Phase 1 single-ascending dose study of DT402 in healthy volunteers, demonstrating an ongoing commitment to innovation.
- The FDA granted Breakthrough Therapy Designation for the DT120 program in GAD, underscoring its potential to address significant unmet need.
- Dosing was initiated in the Phase 3 Voyage study of DT120 ODT in GAD, marking critical progress toward late-stage development.
Advancing late-stage pipeline and expanding clinical reach
In 2025, we continued to build momentum across our clinical programs with key advancements in both research and development.
- Full results from the randomized, placebo-controlled Phase 2b trial of lysergide tartrate in patients with moderate to severe GAD were published in the Journal of the American Medical Association, highlighting the potential of a single-dose treatment across multiple dose levels.
- The pipeline expanded with the initiation of a Phase 2a study of DT402 for autism spectrum disorder (ASD), underscoring the company’s commitment to addressing a broad range of neuropsychiatric conditions.
- Dosing was initiated in Panorama, the second Phase 3 study of DT120 ODT in GAD.
- Progress in late-stage development accelerated with the initiation of dosing and full enrollment of 149 patients in the Phase 3 Emerge study of DT120 ODT for MDD.
- Entering 2026, initial clinical sites were activated for Ascend, the second Phase 3 study evaluating DT120 ODT in MDD, further strengthening the program’s path forward.
A new name, a clear purpose
In 2026, we entered a new era as Definium Therapeutics, beginning to trade on NASDAQ under the ticker DFTX.
The name “Definium” draws from two Latin roots—definio, meaning precision, and infinitum, meaning boundlessness—reflecting our core philosophy.
Together, these ideas define what we stand for: precise science and boundless impact. Precision speaks to the rigor and discipline behind our research and development, while boundlessness captures the ambition to transform outcomes for patients at scale.
The Latest News
